(''Ericsson''). 89 FR 3427–28 (Jan. 18, 2024). The complaint alleged violations of section 337 based on the importation into the United States, the sale for importation, or the sale within the United States after importation of certain electronic computing devices, and components and modules thereof by reason of infringement of claims 1–3, 5–7, 9–11, 14, 15, and 16 of U.S. Patent No. 9,641,841 (''the '841 patent''); claims 1–7 and 10–16 of U.S. Patent No. 10,142,659 (''the '659 patent''); claims 1–19 of U.S. Patent No. 10,708,618 (''the '618 patent''); and claims 1–9 of U.S. Patent No. 10,708,613 (''the '613 patent''). *Id.* The Commission's notice of investigation named the following respondents: Lenovo (United States) Inc. of Morrisville, North Carolina; Lenovo (Shanghai) Electronics Technology Co., Ltd. of Shanghai, China; Lenovo Beijing Co., Limited of Beijing, China; Lenovo PC HK Limited of Hong Kong; Lenovo Information Products (Shenzhen) Co. Ltd. of Shenzhen, China (collectively, ''Lenovo''); and Lenovo Group Limited of Beijing, China (''LGL''). The Office of Unfair Import Investigations (''OUII'') was also named as a party in this investigation. *Id.*

The Commission terminated the investigation as to LGL because LGL does not import into the United States, sell for importation, or sell within the United States the accused products. Order No. 16 (Aug. 20, 2024), *unreviewed by* Comm'n Notice (Sept. 16, 2024).

The Commission terminated the investigation as to all asserted claims of the '613 patent, claims 1–8 and 10–19 of the '618 patent, claims 1–3, 5–7, 9, and 14–16 of the '841 patent, and claims 1–3, 5, 6, and 13–16 of the '659 patent. Order No. 17 (Sept. 9, 2024), *unreviewed by* Comm'n Notice (Oct. 8, 2024); Order No. 33 (Oct. 17, 2024), *unreviewed by* Comm'n Notice (Nov. 5, 2025).

On April 17, 2025, Ericsson and Lenovo filed a joint motion to terminate the investigation in its entirety based upon settlement. On April 28, 2025, OUII filed a response in support of the motion.

On May 8, 2025, the ALJ issued the subject ID (Order No. 39) granting the motion. The ID noted that Commission Rule 210.21(a)(2) provides that ''[a]ny party may move at any time to terminate an investigation in whole or in part as to any or all respondents on the basis of a settlement, a licensing or other agreement . . . .'' ID at 2. The ID found that the motion complies with Commission Rule 210.21(b). *Id.* at 2. The ID further found that in accordance with Commission Rule 210.21(b)(1), the motion states that apart from the Confidential Patent License Agreement and Confidential Arbitration Agreement ''there are no other agreements, written or oral, express or implied between the private parties concerning the subject matter of this Investigation.'' *Id.* at 3. The ID also found that terminating the investigation will not adversely impact the public interest. *Id.* No one petitioned for review of the ID.

The Commission has determined not to review the subject ID. The investigation is hereby terminated in its entirety.

The Commission vote for this determination took place on May 27, 2025. The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: May 28, 2025.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2025–09898 Filed 5–30–25; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1551]

Bulk Manufacturer of Controlled Substances Application: Veranova, L.P.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Veranova, L.P. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before August 1, 2025. Such persons may also file a written request for a hearing on the application on or before August 1, 2025.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on April 17, 2025, Veranova, L.P., 25 Patton Road, Pharmaceutical Service, Devens, Massachusetts 01434–3803, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Lysergic Acid Diethylamide	7315	I
3,4-Methylenedioxymethamphetamine	7405	I
Dimethyltryptamine	7435	I
Amphetamine	1100	II
Methylphenidate	1724	II
Nabilone	7379	II
Hydrocodone	9193	II
Levorphanol	9220	II
Thebaine	9333	II
Alfentanil	9737	II

Controlled substance	Drug code	Schedule
Remifentanil	9739	II
Sufentanil	9740	II

The company plans to bulk manufacture the listed controlled substances in order to support the manufacturing and analytical testing activities at its other Drug Enforcement Administration-registered manufacturing facility. No other activities for these drug codes are authorized for this registration.

Matthew Strait,

Deputy Assistant Administrator.

[FR Doc. 2025–09929 Filed 5–30–25; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1550]

Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: ANI Pharmaceuticals Inc has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on, or objections to the issuance of the proposed registration on or before July 2, 2025. Such persons may also file a written request for a hearing on the application on or before July 2, 2025.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on April 21, 2025, ANI Pharmaceuticals Inc., 70 Lake Drive, East Windsor, New Jersey 08520–5321, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Levorphanol	9220	II
Tapentadol	9780	II

Levorphanol (9220) will be imported for distribution to customers. Tapentadol (9780) will only be used to import small quantities for internal research and reference standards purposes. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Matthew Strait,

Deputy Assistant Administrator.

[FR Doc. 2025–09927 Filed 5–30–25; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

[OMB Number 1105–0030]

Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of a Previously Approved Collection; Electronic Applications for the Attorney General's Honors Program and the Summer Law Intern Program (HP/SLIP)

AGENCY: Office of Attorney Recruitment and Management, Justice Management Division, Department of Justice.

ACTION: 30-Day notice.

SUMMARY: The Office of Attorney Recruitment and Management, Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection was previously published in the **Federal Register** on March 24, 2025, allowing a 60-day comment period.

DATES: Comments are encouraged and will be accepted for 60 days until August 1, 2025.

FOR FURTHER INFORMATION CONTACT: If you have additional comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Deana Willis, Assistant Director, Office of Attorney Recruitment and Management, c/o Rae Ross, 450 5th Street NW, Suite 10200, Washington, DC 20530, 202–514–8900, *Deana.Willis@usdoj.gov.*

SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Bureau of Justice Statistics, including whether the information will have practical utility;

—Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information,